Antibiotics - The Perfect Storm

We need new antibiotics to fight infections caused by resistant bacteria. But the marketplace, the structure of the pharmaceutical industry, regulatory agencies, and difficult science are conspiring to deny us the products we need. This blog will present perspectives and developments in the fight for new antibiotics.

Monday, May 27, 2019

Antibiotic Research and Development - Public vs. Private Funding

Over the past decade, pull incentives as a solution to the broken antibiotic market have been proposed to entice companies into antibioti...

Innovation - response to comment

Google blogger no longer allows me to respond to comments in my own blog. I am obliged to respond, if needed, in a separate blog . . . ...

Thursday, May 2, 2019

Antibiotics, Investors, Where we Go from Here

What do investors think about antibiotics companies? Not much. Paratek, at a price of just $5.42 has a 36% short ratio. That is, 36% of i...

Monday, April 15, 2019

Pull Incentives - Don't Hold Your Breath!

Months ago, long before the 2018 election, I was led to believe that Senate candidate Jackie Rosen of Nevada was seriously interested i...

Friday, March 29, 2019

Non-Traditional Antibacterials

We had our webinar - Clinical development for non-developers Part 3: Non-traditional Approaches yesterday. I encourage everyone int...

Tuesday, March 12, 2019

Regulatory Conundrums

In the absence of any real news on the pull incentive front, I want to turn my attention to the regulatory side of antibiotic developm...

Monday, February 11, 2019

Antibiotics - Play or Pay?

In my last blog I discussed the potential pull incentive proposed in the UK Plan to tackle antimicrobial resistance. One of the other ...

View web version

Powered by Blogger.